Normally I would agree with you 100%. However, we are in the midst of change in how onocology trials are are being reported. This is because of the insights gained from NWBO trials. I expect to see this data released with about 50 different charts explaining the various patient types and degree of success with in each. IMO this data can not be explained adequately by a short announcement, but only through a comprehensive journal article that leaves nothing to imagination. Anything short of that will be confusing and not accurate.
I will preface this by saying I was wrong about TLD being released in the October/September 2020 time frame. I did not grasp, I would say the field did not grasp, the confounding factor of the control group. Control groups affected all oncology trials in the past to the degree that many failed candidates most likely had a degree of efficacy and were successful.
IMO, based on the 2019 presentation, NWBOs trial was wildly successful. However, a single p-value and confidence interval I doubt will adequately explain the results. My guess is we get a publication announcement and date (Feb or March) next.
News 
Market Data 
Discover 
